Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Thomas C. Pearson"'
Autor:
Charlotte Duneton, Rouba Garro, Idelberto R. Badell, Christian P. Larsen, Thomas C. Pearson, Julien Hogan, Geeta Karadkhele
Publikováno v:
Clinical transplantationREFERENCES. 36(3)
The adoption of de-novo belatacept in kidney transplant (kTx) recipients was hampered by an increased risk of acute cellular rejection (ACR) with variation in adopted belatacept based immunosuppressive therapies across centers. We used data from the
Publikováno v:
Journal of Accounting Education. 61:100815
Publikováno v:
Journal of Empirical Legal Studies. 16:381-410
Regulators and shareholders generally oppose any restriction on clients' rights to sue their auditors, believing that such restrictions would impair reporting quality. However, the evidence suggests that the opposition to limitation of liability agre
Publikováno v:
International Journal of Corporate Governance. 10(3-4):248-274
In October 2012, Starbucks UK branch became the subject of massive public criticism over alleged tax avoidance. Despite Starbucks arguing that its transfer pricing practices were in full compliance with regulation, public pressure led Starbucks to ov
Publikováno v:
Curr Transplant Rep
PURPOSE OF REVIEW: Highlight developments in T and B cell biology that are helping elucidate the mechanisms underlying CD28 pathway blockade-mediated inhibition of alloantibodies in transplantation, and discuss recent clinical observations on the imp
Autor:
Geeta Karadkhele, Christian P. Larsen, Aneesh K. Mehta, Thomas C. Pearson, Weiwen Zhang, Julien Hogan, Stephen O. Pastan, Wairimu Magua, Idelberto R. Badell, Marshall Lyon
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES. 21(1)
Introduction Cytomegalovirus (CMV) remains associated with poor outcomes after kidney transplantation (kTx). The impact of belatacept on CMV infection remains understudied. In this study, we assessed the impact of belatacept on patient and graft surv
Autor:
Thomas C. Pearson, Mohua Basu, Jennie P. Perryman, Lisa Petgrave-Nelson, Rachel E. Patzer, Christian P. Larsen, Kevin D. Clark, Sudeshna Paul, Stephen O. Pastan, Kayla D. Smith
Publikováno v:
Clinical Journal of the American Society of Nephrology. 13:620-627
BACKGROUND AND OBJECTIVES: Barriers exist in access to kidney transplantation, where minority and patients with low socioeconomic status are less likely to complete transplant evaluation. The purpose of this study was to examine the effectiveness of
Autor:
Kenneth A. Newell, Ashtar Chami, Cristen Garrett, Allan D. Kirk, J Goldstein, Nicole A. Turgeon, Stephen O. Pastan, Antonio Guasch, Thomas C. Pearson, Rachel E. Patzer, Rebecca Zhang, Andrew B. Adams, Christian P. Larsen
Publikováno v:
American Journal of Transplantation. 17:2922-2936
Belatacept, a T cell costimulation blocker, demonstrated superior renal function, lower cardiovascular risk, and improved graft and patient survival in renal transplant recipients. Despite the potential benefits, adoption of belatacept has been limit
Autor:
Michael J. Englesbe, Thomas C. Pearson
Publikováno v:
American Journal of Transplantation. 21:923-924
Autor:
Heidi Schaefer, David A. McCollum, Robert D. Gordon, Prabhakar K. Baliga, Lawrence Chan, Matthew R. Weir, Sibylle Lawson, Thomas Waid, V. Ram Peddi, Larry B. Melton, Roberto S. Kalil, Shamkant Mulgaonkar, John D. Scandling, Anita T. Patel, Nasser I. Youssef, Lali Anandagoda, Thomas C. Pearson
Publikováno v:
Transplantation. 101:157-165
In the Spare-the-Nephron (STN) Study, kidney transplant recipients randomized about 115 days posttransplant to convert from CNI (calcineurin inhibitor)/MMF to sirolimus (SRL)/MMF had a significantly greater improvement in measured GFR (mGFR) at 12 mo